Copy to clipboard 
Like many global orthopedic companies located in China, Lincotek Medical began to feel the ramifications of COVID-19 in January. During the first months of 2020, the precautions taken at their Wuxi, China, facility were then extended across locations in Europe and the United States. In addition to making sure employees are safe and facilities keep running, Lincotek is investing to grow the company.
“Our decision making in this period was effectively based on three pillars,” said Lincotek CEO Winfried Schaller. “One was the health and wellbeing of our workforce or employees—very, very important. Two was business continuity. We had to secure our business continuity globally; we are an important aspect of the supply chain. And three, we had to make decisions, not only based on COVID but also with the recovery in mind.”
In our video interview with Mr. Schaller, we discuss:
- What challenges Lincotek is hearing from their OEM customers and how the company is responding through business continuity.
- How the company is moving forward with the integration of its CoorsTek Medical acquisition and new investments in machinery, capacity and capabilities.
- What lessons Mr. Schaller and his team have learned thus far in reacting to COVID.
“The question is always, what do you do in such periods? Do you stop your improvement programs? Do you stop your CapEx programs?” Mr. Schaller said. “What we said was, ‘We have to make all decisions with a recovery in mind.’”
